Janus Henderson Group PLC Rain Therapeutics Inc. Transaction History

Janus Henderson Group PLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$7.77 - $12.47 $413,488 - $663,603	53,216 Added 4.15%	1,336,722 $11.7 Million
Q4 2022 Feb 14, 2023	BUY	$5.52 - $8.48 $2.62 Million - $4.02 Million	474,402 Added 58.63%	1,283,506 $10.3 Million
Q3 2022 Nov 14, 2022	BUY	$4.75 - $8.01 $363,132 - $612,356	76,449 Added 10.43%	809,104 $3.9 Million
Q2 2022 Aug 15, 2022	BUY	$2.21 - $5.56 $211,910 - $533,131	95,887 Added 15.06%	732,655 $4.08 Million
Q1 2022 May 16, 2022	SELL	$5.07 - $13.68 $3.01 Million - $8.12 Million	-593,687 Reduced 48.25%	636,768 $3.22 Million
Q4 2021 Feb 14, 2022	SELL	$11.91 - $17.0 $2.04 Million - $2.92 Million	-171,619 Reduced 12.24%	1,230,455 $15.8 Million
Q3 2021 Nov 16, 2021	SELL	$13.21 - $20.91 $667,646 - $1.06 Million	-50,541 Reduced 3.48%	1,402,074 $20.5 Million
Q2 2021 Aug 16, 2021	BUY	$15.08 - $20.3 $21.9 Million - $29.5 Million	1,452,615 New	1,452,615 $21.5 Million

122K

Ticker RAIN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,837,400
Description
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.